Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2839434 | 0.93 | S1PR1 (0.78) | S1PR1MAPTPOLBRXFP1 | |
| SCHEMBL3756375 | 0.92 | S1PR1 (0.80) | S1PR1MAPTPOLBRXFP1 | |
| SCHEMBL3760058 | 0.92 | S1PR1 (0.80) | S1PR1MAPTPOLBRXFP1 | |
| SCHEMBL3771118 | 0.89 | S1PR1 (1.00) | S1PR1MAPTPOLBRXFP1TP53 | |
| SCHEMBL3761240 | 0.85 | S1PR1 (0.64) | S1PR1MAPTPOLBRXFP1 | |
| SCHEMBL3761501 | 0.84 | S1PR1 (0.67) | S1PR1MAPTPOLBRXFP1 | |
| SCHEMBL3761555 | 0.84 | S1PR1 (0.84) | S1PR1MAPTPOLB | |
| SCHEMBL12997627 | 0.84 | S1PR1 (0.70) | S1PR1MAPTPOLBRXFP1 | |
| SCHEMBL3763984 | 0.83 | S1PR1 (0.59) | S1PR1MAPTPOLBRXFP1TP53 | |
| SCHEMBL12997625 | 0.83 | S1PR1 (0.72) | S1PR1MAPTPOLBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193126-B1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO SA (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2193126-B1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO SA (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8404676-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404676-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404676-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| EP-2193126-A1 | OXADIAZOLE DIARYL COMPOUNDS | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043890-A1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043890-A1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | S1PR1 277/4885MAPT 3491/4885POLB 1918/4885 |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | S1PR1 174/4885MAPT 3516/4885POLB 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.